Hopp til hovedinnhold

Peptic ulcer disease

Sist revidert:
Sist revidert av:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/documents-in-english/peptic-ulcer-disease/ 

Key facts

Definitions

Incidence/prevalence

Etiology and pathology

Risk factors

ICPC

ICD-10

Diagnosis

Diagnostic criteria

Differentials

History

Physicals

Lab tests in general practice

Investigations

Referral

Management

Treatment aims

Overview of management

Self treatment

Medications

Surgery

Prophylactic treatment

Clinical course, complications and prognosis

Clinical course

Complications

Prognosis

Follow-up

Plan

What to control

Patient information

What to inform the patient about

Available patient information leaflets

Animations

Illustrations

Images

Drawings

Kilder

Referanser

  1. Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: the Sørreisa gastrointestinal disorder study. Gut 1990; 31: 989-92. PubMed  
  2. Graham DY. Can therapy ever be denied for Helicobacter pylori infection?. Gastroenterology 1997; 113: S113-7. PubMed  
  3. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2-17. PubMed  
  4. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007; 76: 1005-12. PubMed  
  5. Ziegler AB. The role of proton pump inhibitors in acute stress ulcer prophylaxis in mechanically ventilated patients. Dimens Crit Care Nurs 2005; 24: 109-14. PubMed  
  6. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9. Journal of the American Medical Association  
  7. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52. Gastroenterology  
  8. Bytzer P, Teglbjaerg PS, for the Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis-results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96: 1409-16. PubMed  
  9. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22. PubMed  
  10. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91: 2080-6. PubMed  
  11. Collier DS, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 1985; 26: 359-63. Gut  
  12. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 683-9. Gastroenterology  
  13. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9. PubMed  
  14. De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-9. British Medical Journal  
  15. Dalton SO, Johansen C, Mellemkjær L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64. PubMed  
  16. Cerezo JG, Hristov RL, Carcas Sansuán AJ, Vázquez Rodríguez JJ. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharm 2003; 59: 169-175. PubMed  
  17. Garcia Rodriguez LA, et al. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. British Journal of Clinical Pharmacology 2001; 52: 563-71. PubMed  
  18. Derry S, Loke YK. Risk of gastrointestinal haemorrhage withlong term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7. PubMed  
  19. Johannessen T, Petersen H, Kleveland PM et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25: 689-97. PubMed  
  20. Spiegelhalter DJ, Crean GP, Holden R, Knill-Jones RP. Taking a calculated risk: predictive scoring systems in dyspepsia. Scand J Gastroenterol Supp 1987; 128: 152-60. PubMed  
  21. Johannessen T, Petersen H, Kristensen P et al. The intensity and variability of symptoms in dyspepsia. Scand J Prim Health Care 1993; 11: 50-5. PubMed  
  22. Cappell MS. Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 2003; 32: 263-308. PubMed  
  23. Hilton D, Iman N, Burke GJ, Moore A, O'Mara G, Signorini D, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96: 380-4. PubMed  
  24. Martinez JP, Mattu A. Abdominal pain in the elderly. Emerg Med Clin North Am 2006; 24: 371-88. PubMed  
  25. Makristathis A, Barousch W, Pasching E, Binder C, Kuderna C, Apfalter P, et al. Two immunoassays and PCR for detection of Helicobacter pylori in stool specimens from paediatric patients before and after eradication therapy. J Clin Microbiol 2000; 38: 3710-4. PubMed  
  26. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection by stool antigen determination: A systematic review. Am J Gastroenterol 2001; 96: 2829-38. PubMed  
  27. Andrews J, Marsden B, Brown D, Wong VS, Wood E, Kelsey M. Comparison of three stool antigen tests for Helicobacter pylori detection. J Clin Pathol 2003; 56: 769-71. PubMed  
  28. Makristathis A, Barousch W, Pasching E, Binder C, Kuderna C, Apfalter P, et al. Two immunoassays and PCR for detection of Helicobacter pylori in stool specimens from paediatric patients before and after eradication therapy. J Clin Microbiol 2000; 38: 3710-4. PubMed  
  29. Asante MA, Mendall MA, Finlayson C, Ballam L, Northfield T. Screening dyspeptic patients for Helicobacter pylori prior to endoscopy: laboratory or near-patient testing?. Eur J Gastroenterol Hepatol 1998; 10: 843-6. PubMed  
  30. Garza-Gonzalez E, Bosques-Padilla FJ, Tijerina-Menchaca R, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Comparision of endoscopy-based and serum-based methods for the diagnosis of Helicobacter pylori. Can J Gastroenterol 2003; 17: 101-6. PubMed  
  31. Laine L, Knigge K, Faigel D et al. Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing?. Am J Gastroenterol 1999; 94: 3464-7. PubMed  
  32. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80. Gastroenterology  
  33. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow-up of a randomsed trial. Gut 2004; 53: 1758-63. Gut  
  34. Jarbol DE, Kragstrup J, Stovring H, Havelund T, Schaffalitzky de Muckadell OB. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster randomized trial. Am J Gastroenterol 2006; 101: 1200-8. PubMed  
  35. Winstead NS, Wilcox CM. Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1371-7. PubMed  
  36. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 848-63. PubMed  
  37. Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician 2007; 75: 351-8. PubMed  
  38. Malfertheiner P, Megraud F, O'Morain C and for the European Helicobacter Study Group. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007; 56: 772-81. Gut  
  39. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998; 115:1272-1277. PubMed  
  40. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycicn and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-29. PubMed  
  41. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559-68. PubMed  
  42. Lara LF, Cisneros G, Gurney M, Van Ness M, Jarjoura D, Moauro B, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003; 163: 2079-84. PubMed  
  43. Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162: 153-60. PubMed  
  44. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5. PubMed  
  45. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. Gut 2007; 56: 475-9. Gut  
  46. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vanderbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999;43:511-415. PubMed  
  47. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol. 2006; 20: 113-7. PubMed  
  48. Wu JC, Chan FK, Ching JY, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 53: 174-79. Gut  
  49. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ 2004; 328: 1417-9. PubMed  
  50. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. The effect of population H pylori screening and treatment on dyspepsia and quality of life in the community: results of a randomised controlled trial. Lancet 2000; 355: 1665-9. PubMed  
  51. Wildner-Christensen M, Hansen JM, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003; 125: 372-9. Gastroenterology  
  52. Veldhuyzen van Zanten SJ, Flook N, et al. An evidence-based approach to the management of univestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 162 (suppl 12): S3-S23.
  53. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software. The Cochrane Library  
  54. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33. PubMed  
  55. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-8. PubMed  
  56. Yeomans ND, Hawkey C, Lanas A, et al. Prevalence of gastric and duodenal ulcers during "low dose" aspirin. Gastroenterology 2002; 122: A-87.
  57. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8. PubMed  
  58. Johansen M. Platehemmerbehandling ved tidligere gastrointestinal blødning forårsaket av acetylsalisylsyre. Tidsskr Nor Lægeforen 2006; 126: 2802-4. PubMed  
  59. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteorarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-83. PubMed  
  60. Pomp E. En kritisk vurdering av bivirkningsdata for COX-2-hemmere. Tidsskr Nor Lægeforen 2002; 122: 476-80. PubMed  
  61. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-90. PubMed  
  62. Chan FKL, Ching JYL, Hung LCT. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-44. PubMed  
  63. Aabakken L, Carlsen E. Gastroenterologiske rutiner ved Ullevål sykehus. 6. utgave. Oslo: 2000.
  64. Schaffalitzky de Muckadell OB. Syrepumpehæmmer ved blødende mavesår?. Ugeskr Læger 2006; 168: 1024-6. PubMed  
  65. Eisen GM, Dominitz JA, Faigel DO, Goldstein JL, Kalloo AN, Petersen BT, et al., for the American Society for Gastrointestinal Endoscopy. Standards of Practice Committee. An annotated algorithmic approach to upper gastrointestinal bleeding. Gastrointest Endosc 2001; 53: 853-8. PubMed  
  66. Tsibouris P, Zintzaras E, Lappas C, et al. High-dose pantoprazole continuous infusion is superior to somatostatin after endoscopic hemostasis in patients with peptic ulcer bleeding. Am J Gastroeneterol 2007; 102: 1192-9. PubMed  
  67. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568. PubMed  
  68. Leontiadis GI, McIntyre L, Sharma VK et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. The Cochrane Database of Systematic Reviews 2004, Issue 3. CD002094. Cochrane (DOI)  
  69. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19: 617-29. PubMed  
  70. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9. Annals of Internal Medicine  
  71. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev, issue 4, 2002. The Cochrane Library  
  72. Liu C-C, Lee C-L, Chan C-C. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: A 5-year prospective, randomized, controlled study. Arch Intern Med 2003; 163: 2020-4. PubMed  
  73. Lanas AI, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109: 1124-33. Gastroenterology  
  74. Sanabria A, Morales C, Villegas M. Laparoscopic repair for perforated peptic ulcer disease. Cochrane Database Syst Rev 2005; 4. The Cochrane Library  
  75. Ljungdahl M, Eriksson L-G, Nyman R, Gustavsson S. Artärembolisering kan ofte ersätta kirurgi ved blödande ulkus. Läkartidningen 2003; 100: 768-72.
  76. Behrman SW. Management of complicated peptic ulcer disease. Arch Surg 2005; 140: 201-8. PubMed  
  77. Petersen H, Kristensen P, Johannessen T, Kleveland PM, Dybdahl JH. The natural course of peptic ulcer disease and its predictors. Scand J Gastroenterol 1995; 30: 17-24 PubMed  
  78. Hopkins EJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52. PubMed  
  79. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157-63. PubMed  
  80. Forsmo HM, Vandvik PO, Glomsaker T. Ulcus perforatum - et 12-årsmateriale. Tidsskr Nor Lægeforen 2005; 125: 1822-4. PubMed  
  81. Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995; 90: 1769-70. PubMed  
  82. Mohammed Z, Abu-Mahfouz MD, Prasad VM, Santogade P, Cutler AF. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 1997; 11: 2025-8..
  83. Chey WD, Murthy U, Toskes P et al. The 13 C-urea blood test accurately detects active Helicobacter pylori infection: Am J Gastroenterol 1999 Jun;94:1522-4.
  • Terje Johannessen, professor i allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Hermod Petersen, professor og overlege, Norges teknisk-naturvitenskapelige universitet og Medisinsk avdeling, Regionsykehuset i Trondheim